US stock · Healthcare sector · Medical Devices
Company Logo

Abbott Laboratories

ABTNYSE

109.50

USD
+2.53
(+2.36%)
Market Open
24.83P/E
22Forward P/E
1.20P/E to S&P500
191.719BMarket CAP
1.72%Div Yield

Abbott Laboratories

NYSE:ABT

RECENT
PRICE

109.50

P/E
RATIO

24.83

(PEG:0.43)

P/E RATIO
RELATIVE
TO S&P

1.20

DIV
YLD

1.50%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

0.72 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 06/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

TTM

Fiscal year

14.69

1.12

2.61

1.16

16.79

2.34

2.29

1.27

19.13

3.16

3.92

1.41

19.89

3.72

4.00

1.56

22.73

2.99

4.99

1.73

24.74

3.01

4.76

1.87

25.29

3.78

4.77

2.02

14.11

1.66

1.41

0.57

13.43

1.51

1.72

0.89

13.86

3.00

1.26

0.98

14.16

0.95

1.41

1.04

15.71

0.27

2.54

1.06

17.42

1.35

2.79

1.12

18.10

2.09

2.55

1.29

19.54

2.54

3.23

1.45

24.32

3.99

4.88

1.81

25.23

4.38

4.62

1.83

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.87

9.19

1.07

11.52

0.83

11.32

0.70

14.78

0.66

14.47

0.95

15.56

1.14

16.95

0.74

16.26

0.71

14.27

0.75

14.40

0.76

13.94

0.65

17.72

0.79

17.39

0.93

17.64

1.23

18.51

1.06

20.21

1.03

19.76

CAPEX per share

Book Value per share

1,530

1,543

1,544

1,546

1,547

1,570

1,577

1,548

1,508

1,473

1,473

1,744

1,756

1,763

1,771

1,771

1,764

Comm.Shares outs.(m)

19.2

1.1

5.4%

11.2

0.6

4.9%

8.3

0.4

5.4%

6.2

0.1

6.7%

8.1

0.4

7.1%

8.1

0.5

7.7%

7.9

0.5

6.7%

21.3

1.3

1.6%

27.0

1.5

2.2%

15.3

0.8

2.1%

42.4

1.9

2.6%

177.2

7.5

2.2%

47.6

1.9

1.8%

38.3

1.6

1.6%

37.7

1.0

1.5%

30.5

1.0

1.5%

24.8

1.2

1.5%

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (31/3/22 | Q1)

Total liabilities
$38,378 m.

Total assets
$74,007 m.

Long-term debt
$17,086 m.

Cash and equiv.
$7,675 m.

Goodwill $23,179 m.

Retained earnings $33,295 m.

Common stock 1,751 m. shares

Market Capitalisation
$187,298 m. (as of 29/6/22)

38,851

14.8%

39,874

20.3%

21,848

12.0%

20,247

12.8%

20,405

14.1%

20,853

15.3%

27,390

6.3%

30,578

11.9%

31,904

14.2%

34,608

15.5%

43,075

19.6%

44,514

20.5%

Revenue (m)

Operating margin

3,044

4,728

2,783

5,963

1,719

2,576

1,548

2,284

1,472

4,423

1,353

1,400

3,021

477

3,278

2,368

3,014

3,687

3,327

4,495

3,538

7,071

3,427

7,725

Depreciation (m)

Net profit (m)

9.0%

12.2%

4.8%

15.0%

5.5%

11.8%

31.7%

11.3%

18.1%

21.7%

24.8%

6.7%

84.2%

1.7%

18.8%

7.7%

9.6%

11.6%

10.0%

13.0%

13.9%

16.4%

14.3%

17.2%

Income tax rate

Net profit margin

8,289

12,040

24,440

18,042

18,085

26,721

9,740

3,388

25,171

4,729

3,408

21,526

4,969

5,871

21,211

20,116

20,681

20,538

11,235

27,210

30,897

5,620

19,359

30,524

4,804

16,661

31,088

8,534

19,429

32,784

11,134

18,252

35,802

10,782

17,086

35,399

Working capital (m)

Long-term debt (m)

Equity (m)

11.7%

9.5%

19.3%

12.1%

10.2%

22.3%

8.1%

6.7%

10.2%

7.2%

7.8%

10.6%

13.2%

12.6%

20.9%

3.6%

4.2%

6.8%

0.8%

4.3%

1.5%

5.2%

5.6%

7.8%

7.6%

7.0%

11.9%

8.2%

7.7%

13.7%

12.2%

11.7%

19.8%

13.4%

13.0%

21.8%

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

4,140

7,118

10,079

Receivables

5,425

6,414

6,487

Inventory

4,316

5,012

5,157

Other

1,786

1,867

2,346

Current assets

15,667

20,441

24,239

Acc. Payable

3,252

3,946

4,408

Debt due

1,478

220

754

Other

6,133

7,741

7,943

Current liab.

10,863

11,907

13,105

37.9%

40.3%

46.6%

73.8%

65.8%

114.1%

41.2%

136.1%

67.4%

198.3%

(9.9)%

99.0%

(287.6)%

60.3%

16.6%

45.1%

38.4%

66.4%

43.0%

51.8%

54.7%

63.6%

58.1%

92.8%

Plowback ratio

Div.&Repurch. to FCF

Abbott Laboratories (US) started trading on March 1, 1937 (cik: 0000001800), operates in the Healthcare sector (Medical Devices industry), has 113,000 full-time employees, and is led by Mr. Robert Ford. Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

12.23%

3.41%

Cash flow

20.16%

13.94%

Earnings

132.84%

46.96%

Dividends

14.90%

8.20%

Book value

3.83%

4.54%

Insider trading

Type

Shares

Date

Earnhardt Lisa D

InKind

19,592

06/10/22

Earnhardt Lisa D

InKind

2,882

06/10/22

Ginascol John F

InKind

1,768

06/03/22

Wainer Andrea F

InKind

1,768

06/03/22

Woodgrift Randel William

Exempt

24,000

05/04/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

7,726

7,328

8,853

10,701

34,608

2021

10,456

10,223

10,928

11,468

43,075

2022

11,895

- -

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

0.32

0.30

0.70

1.22

2.54

2021

1.01

0.67

1.19

1.12

3.99

2022

1.40

- -

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

0.36

0.36

0.36

0.36

1.45

2021

0.45

0.45

0.45

0.45

1.81

2022

0.48

- -

- -

- -

- -

06/23/2022

Latest Report of Baby’s Death After Consuming Formula Mentions Cronobacter Bacteria

The Wall Street Journal - Read more...

06/22/2022

FDA Investigating Report of Baby’s Death After Consuming Abbott Formula

The Wall Street Journal - Read more...

06/16/2022

Abbott Halts Production at Michigan Baby-Formula Plant

The Wall Street Journal - Read more...

06/12/2022

Enfamil and Smaller Baby-Formula Brands Test Dominance of Similac

The Wall Street Journal - Read more...

06/08/2022

Abbott Received Earlier Warning on Formula Plant

The Wall Street Journal - Read more...

06/04/2022

Baby-Formula Shortage Expected to Persist Weeks Longer

The Wall Street Journal - Read more...

05/25/2022

FDA Chief Takes Aim at Abbott Laboratories

The Wall Street Journal - Read more...

05/24/2022

Abbott to Release 300,000 Specialty Baby Formula Cans

The Wall Street Journal - Read more...

05/24/2022

Why Is There a Baby Formula Shortage? What to Know and Why It’s Getting Worse

The Wall Street Journal - Read more...

05/22/2022

Abbott CEO Apologizes for Company’s Role in Baby-Formula Shortage

The Wall Street Journal - Read more...

05/17/2022

Gerber Owner Nestlé to Fly Extra Baby Formula to the U.S.

The Wall Street Journal - Read more...

05/12/2022

Baby Formula Shortage Could Leave Parents Scrambling for Months

The Wall Street Journal - Read more...

05/11/2022

Abbott Could Restart Baby Formula Production Within Two Weeks

The Wall Street Journal - Read more...

04/20/2022

Lucky Charms Sickness Complaints Spread Rapidly, Adding Complexity to Safety Probe

The Wall Street Journal - Read more...

04/18/2022

Contaminated-Baby-Formula Investigation Turns Murky

The Wall Street Journal - Read more...

03/02/2022

SoFi Technologies, AMC, Salesforce, Snowflake: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

03/01/2022

Abbott Recalls More Baby Formula

The Wall Street Journal - Read more...

02/18/2022

Abbott Recalls Baby Formula After Reports of Bacterial Contamination

The Wall Street Journal - Read more...

01/26/2022

Abbott’s Rapid Covid-19 Tests Boost Quarterly Sales Growth

The Wall Street Journal - Read more...

01/26/2022

Tesla, Microsoft, Boeing, Texas Instruments: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

10/20/2021

Novavax, Tesla, Netflix, United: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

04/20/2021

Kansas City Southern, IBM, United Airlines: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

01/27/2021

GameStop, Microsoft, AMC: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

08/26/2020

Abbott’s $5 Covid-19 Rapid Antigen Test Gets Emergency-Use Status From FDA

The Wall Street Journal - Read more...

07/16/2020

Abbott Laboratories Gets Boost From U.S. Covid-19 Testing

The Wall Street Journal - Read more...